On the other hand, recent clinical trials showed that the addition of PD‐1 or PD‐L1 inhibitor with platinum‐doublet resulted in significantly longer overall and progression‐free survival (PFS) than placebo with platinum‐doublet across all categories of PD‐L1 expression in patients with NSCLC.4, 5. Here, PDCD1 is linked to non-small cell lung carcinoma.